12th Aug 2026 14:28
(Alliance News) - Daiichi Sankyo Co Ltd on Wednesday said Enhertu, which it is developing alongside AstraZeneca PLC, received another approval in China.
Tokyo-based Daiichi said the drug was backed by China's National Medical Products Administration for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer.
The approval, which is based on phase 3 trial data results, is for Enhertu plus pertuzumab.
Daiichi said the combination reduced the risk of disease progression or death by 44% compared to taxane, trastuzumab and pertuzumab in patients with HER2 positive metastatic breast cancer who had not received prior chemotherapy or HER2 targeted therapy or had received neoadjuvant or adjuvant HER2 targeted therapy more than six months before the diagnosis of advanced or metastatic disease.
Daiichi shares had closed flat at JPY2,805.00 each on Wednesday in Tokyo, while Cambridge-based AstraZeneca traded 1.5% lower at 11,672.00 pence each on Wednesday afternoon in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca